Navigation Links
BioMed Realty Trust Prices Public Offering Of 15,000,000 Shares Of Common Stock
Date:3/27/2013

rities laws of such state or other jurisdiction.  The offering of BioMed Realty's common stock will be made only by means of a prospectus and a related prospectus supplement, copies of which may be obtained by contacting Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, at 1-866-718-1649 or by email at prospectus@morganstanley.com; Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, Florida 33716, by calling toll-free at 1-800-248-8863 or by email at prospectus@raymondjames.com; UBS Securities LLC, Attention:  Prospectus Department, 299 Park Avenue, New York, New York 10171, or toll-free at 1-888-827-7275; Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, at 1-800-326-5897 or by email at cmclientsupport@wellsfargo.com; or KeyBanc Capital Markets Inc., Attention: Prospectus Delivery Department, 127 Public Square, 4th Floor, Cleveland, Ohio 44114, telephone: 1-800-859-1783.

About BioMed Realty Trust

BioMed Realty delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 13.2 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Francisco, Maryland, San Diego, New York/'/>"/>

SOURCE BioMed Realty Trust, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medical Device Developers - Network at BIOMEDevice Boston Next Week
2. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
3. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
4. Fluke Biomedical launches speedy new ProSim™ SPOT Light SpO2 Functional Tester
5. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
6. Fluke Biomedical device first to achieve environmentally-friendly label
7. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
8. 81,200 Square Foot Lease Extension In San Diego Through 2018 Signed By Vertex Pharmaceuticals And BioMed Realty
9. The Biomedical Device Industry in America: Challenges at Home and Abroad
10. BioMed Diagnostics Microbiology Diagnostic Devices Now Available Worldwide Through Distribution Agreement With VWR International, LLC
11. BioMed Realty Trust Converts $156.4 Million Of Its Senior Unsecured Term Loan To 100 Million Pounds Sterling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014   Wellcentive , ... (PHM) for healthcare organizations, announced today being named ... 2014 Intel Innovation Award .  Sponsored by Intel, ... in its fourth year, recognizes companies developing leading-edge ... healthcare delivery processes. Wellcentive,s ...
(Date:11/21/2014)... Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... its offering of $80,000,000 aggregate principal amount of 5.25% ... a private offering within the United States ... institutional buyers pursuant to Rule 144A under the Securities ... has also granted the initial purchasers an option to ...
(Date:11/18/2014)... WALTHAM, Mass. , Nov. 18, 2014 ... one of the leading medical device and services providers ... Motion,s exclusive partner for Respiratory Motion,s innovative respiratory depression ... Respiratory Motion and IMI are working together to connect ... IMI has a long history of bringing innovative medical ...
Breaking Medicine Technology:Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4
... Launches 1,000-Patient Lung Cancer Diversity Study, CHICAGO, June ... the leading cause of cancer death in,African-Americans, with ... deaths expected this year.(i) Equally devastating, lung,cancer is ... men and the,second leading cause of cancer death ...
... an overall CBR of 52% which compares ... CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ - ... focused on,endocrine therapy and oncology, today announced ... outlining Phase 1 and,Phase 2 results for ...
Cached Medicine Technology:Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 2Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 3Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 4Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 5Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 6Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 7Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 8Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 9Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 10Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 11AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 2AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 4
(Date:11/21/2014)... Florida (PRWEB) November 21, 2014 Nature’s Sleep is ... Sleep contest . The contest calls for the creation of any ... a photo — that encompasses sleep, a bed or a mattress. ... year,” said Alan Hirschhorn, Vice President of Marketing for Nature’s Sleep, ... an array of more than 10,000 creative entries from some very ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, 2014 ... of a still-beating heart has the potential to improve the ... new study. Heart patients who received the gel implant ... hundreds of feet farther during a six-minute walk test, said ... cardiovascular division at Washington University School of Medicine and a ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. ... excess or binge drink are not alcoholics, a new U.S. ... who drink too much aren,t dependent on alcohol. But one ... Centers for Disease Control and Prevention. , , "A lot of ... alcoholics," said study co-author Dr. Robert Brewer, the leader of ...
(Date:11/18/2014)... November 18, 2014 Cristcot Inc., ... development and commercialization of specialized drug delivery systems, ... granted Cristcot a patent for the technology, which ... Sephure®. , The patent was awarded to ... rights have been assigned to Cristcot Inc. The ...
(Date:11/18/2014)... HealthDay Reporter MONDAY, ... cholesterol down to extremely low levels with a combination ... in high-risk patients with clogged arteries, a new study ... when taking Vytorin, a drug that combines a cholesterol-lowering ... said principal investigator Dr. Christopher Cannon, a cardiologist at ...
Breaking Medicine News(10 mins):Health News:Nature’s Sleep Kicks Off their 2nd Art Of Sleep Contest 2Health News:Gel Implant Might Help Fight Heart Failure 2Health News:Gel Implant Might Help Fight Heart Failure 3Health News:Many People Who Drink a Lot Aren't Alcoholics: CDC 2Health News:Many People Who Drink a Lot Aren't Alcoholics: CDC 3Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 3
... HARRISBURG, Pa. , Sept. 8 ... for subsidized health insurance coverage, state Insurance Commissioner Joel Ario today urged ... that will give Pennsylvania and other states tools needed to fix the ... , "Lost in the din of the recent town hall ...
... Delta Health , an InfoLogix, ... that it has been selected by Hennepin County Medical Center in ... impact margins through productivity management. , , (Logo: ... , Delta Health has helped hospitals across North America ...
... , NEW YORK, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) ... that it has filed a patent for a novel ... thus has blockbuster potential as a new anti-cancer drug. ... which is highly reactive to prostate cancer cells, and ...
... Sept. 8 MRSA Survivors Network, the Chicago-based nonprofit and official ... lift the veil of secrecy surrounding MRSA. The history making ... October 1st. The 2009 theme is "You Can Not Change What ... http://www.newscom.com/cgi-bin/prnh/20090825/DC65136LOGO ) , , Founder ...
... , NEW YORK, Sept. 8 NeoStem, ... pioneering the pre-disease collection, processing and long-term storage of adult stem ... Robin Smith, M.D., MBA, will present on the Company,s latest strategic ... New York Palace Hotel in New York City on September 9-11, ...
... , , WALTHAM, Mass., ... the global authority on medical technology market intelligence, the ... experience considerable growth in sales over the next five ... 2009 report finds, however, that product safety issues ...
Cached Medicine News:Health News:Insurance Commissioner Says Federal Health Care Reform Necessary to Fix a Broken System 2Health News:Delta Health, an InfoLogix Company, Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 2Health News:Delta Health, an InfoLogix Company, Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 3Health News:Genova files patent for new prostate cancer treatment 2Health News:MRSA Activists to Lift the Veil of Secrecy on World MRSA Day 2Health News:NeoStem to Present at Rodman & Renshaw's 11th Annual Healthcare Conference 2Health News:NeoStem to Present at Rodman & Renshaw's 11th Annual Healthcare Conference 3Health News:Will the FDA Ban Hydroquinone in Pigment Control Products? 2Health News:Will the FDA Ban Hydroquinone in Pigment Control Products? 3
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
... people are diagnosed with varicose veins every ... never seek treament and are apprehensive of ... them an effective alternative to conventional therapies., ... hook phlebectomy), is considered a laborious procedure ...
Inquire...
...
Medicine Products: